Top

Published in:

01-01-2016 | Original Article

Prognostic value of long non-coding RNA MALAT1 in cancer patients

Authors: Yihua Wu, Wei Lu, Jinming Xu, Yu Shi, Honghe Zhang, Dajing Xia

Published in: Tumor Biology | Issue 1/2016

Abstract

Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) was identified to be the first long non-coding RNA as a biomarker of independent prognostic value for early stage non-small cell lung cancer patient survival. In recent years, the association between upregulated tissue MALAT1 level and incidence of various cancers including bladder cancer, colorectal cancer, and renal cancer has been widely discussed. The aim of our present study was to assess the potential prognostic value of MALAT1 in various human cancers. PubMed, Embase, Ovid, and Cochrane Library databases were systematically searched, and eligible studies evaluating the prognostic value of MALAT1 in various cancers were included. Finally, 11 studies encompassing 1216 participants reporting with sufficient data were enrolled in the current meta-analysis. The pooled hazard ratio (HR) was 2.05 (95 % confidence interval (CI) 1.64–2.55, p < 0.01) for overall survival (OS) and 2.66 (95 % CI 1.86–3.80, p < 0.01) for disease-free survival (DFS). In conclusion, high tissue MALAT1 level was associated with an inferior clinical outcome in various cancers, suggesting that MALAT1 might serve as a potential prognostic biomarker for various cancers.

Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799–816. doi:10.1038/nature05874.CrossRefPubMed

Costa FF. Non-coding RNAs: meet thy masters. Bioessays. 2010;32(7):599–608. doi:10.1002/bies.200900112.CrossRefPubMed

Struhl K. Transcriptional noise and the fidelity of initiation by RNA polymerase II. Nat Struct Mol Biol. 2007;14(2):103–5. doi:10.1038/nsmb0207-103.CrossRefPubMed

Ebisuya M, Yamamoto T, Nakajima M, Nishida E. Ripples from neighbouring transcription. Nat Cell Biol. 2008;10(9):1106–13. doi:10.1038/ncb1771.CrossRefPubMed

Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9. doi:10.1038/nrg2521.CrossRefPubMed

Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, Halling ML, Ganapathiraju SC, et al. Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 2008;17(5):642–55. doi:10.1093/hmg/ddm336.CrossRefPubMed

Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38. doi:10.1016/j.molcel.2010.08.011.CrossRefPubMedPubMedCentral

Wilusz JE, Freier SM, Spector DL. 3’ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008;135(5):919–32. doi:10.1016/j.cell.2008.10.012.CrossRefPubMedPubMedCentral

Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41. doi:10.1038/sj.onc.1206928.CrossRefPubMed

10.

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9. doi:10.1158/0008-5472.can-12-2850.CrossRefPubMed

11.

Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics. 2007;8:39. doi:10.1186/1471-2164-8-39.CrossRefPubMedPubMedCentral

12.

Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26(6):851–8. doi:10.1038/sj.onc.1209846.CrossRefPubMed

13.

Yang MH, Hu ZY, Xu C, Xie LY, Wang XY, Chen SY, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta. 2015;1852(1):166–74. doi:10.1016/j.bbadis.2014.11.013.CrossRefPubMed

14.

Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther. 2014;15(6):806–14. doi:10.4161/cbt.28584.CrossRefPubMedPubMedCentral

15.

Wang J, Su L, Chen X, Li P, Cai Q, Yu B, et al. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomed Pharmacother. 2014;68(5):557–64. doi:10.1016/j.biopha.2014.04.007.CrossRefPubMed

16.

Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012;8(9):2289–94. doi:10.1039/c2mb25070e.CrossRefPubMed

17.

Tano K, Akimitsu N. Long non-coding RNAs in cancer progression. Front Genet. 2012;3:219. doi:10.3389/fgene.2012.00219.CrossRefPubMedPubMedCentral

18.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41. doi:10.1016/j.ijsu.2010.02.007.CrossRefPubMed

19.

Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.1186/1471-2288-12-9.CrossRefPubMedPubMedCentral

20.

Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29(3):1810–6. doi:10.1007/s12032-011-0004-z.CrossRefPubMed

21.

Liu JH, Chen G, Dang YW, Li CJ, Luo DZ. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac J Cancer Prev. 2014;15(7):2971–7.CrossRefPubMed

22.

Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P et al. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi:10.1007/s13277-014-2969-7

23.

Okugawa Y, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35(12):2731–9. doi:10.1093/carcin/bgu200.CrossRefPubMedPubMedCentral

24.

Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi:10.1007/s13277-014-2850-8

25.

Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6(12):1984–92. doi:10.1097/JTO.0b013e3182307eac.CrossRefPubMed

26.

Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang Z. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neurooncol. 2015;121(1):101–8. doi:10.1007/s11060-014-1613-0.CrossRefPubMed

27.

Zhang HM, Yang FQ, Chen SJ, Che J, Zheng JH. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi:10.1007/s13277-014-2925-6

28.

Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7(6):3174–81.PubMedPubMedCentral

29.

Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. TGF-beta-induced upregulation of MALAT1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20(6):1531–41. doi:10.1158/1078-0432.ccr-13-1455.CrossRefPubMed

30.

Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jockel KH, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes. 2013;6:518. doi:10.1186/1756-0500-6-518.CrossRefPubMedPubMedCentral

31.

Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485–92.PubMed

32.

Li S, Wang Q, Qiang Q, Shan H, Shi M, Chen B et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor. Journal of cancer research and clinical oncology. 2015. doi:10.1007/s00432-015-1951-0

33.

Wang X, Li M, Wang Z, Han S, Tang X, Ge Y et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217inhibits proliferation, migration and invasion of esophageal squamous cell carcinoma cells. The Journal of biological chemistry. 2014. doi:10.1074/jbc.M114.596866

34.

Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway. PloS one. 2013;8(11):e78700. doi:10.1371/journal.pone.0078700.CrossRefPubMedPubMedCentral

Title: Prognostic value of long non-coding RNA MALAT1 in cancer patients
Authors: Yihua Wu
Wei Lu
Jinming Xu
Yu Shi
Honghe Zhang
Dajing Xia
Publication date: 01-01-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3870-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma

Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screening

The role of TARBP2 in the development and progression of cancers

Glutathione S-transferase P1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: evidence from an enlarged study

RETRACTED ARTICLE: Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis

Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer